SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Clinical trial NCT05093387 · WITHDRAWN

Trial details

NCT number: NCT05093387
Sponsor: Northwestern University
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 Breast Inflammatory Carcinoma Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8

Start date: 2022-11-10
Primary completion: 2022-11-10
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.